TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07873931: A Phase 1, Multicenter, Open-Label Study of BMS-986553, CD19 In Vivo Chimeric Antigen Receptor (CAR) T Cells, in Participants With Refractory Autoimmune Diseases

Sponsor: Bristol-Myers Squibb · Phase: PHASE1 · Area: IMMUNOLOGY · Target Enrollment: 60 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$281,520

Rescue Site Savings

+$187,680

Unlock Full NCT07873931 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07873931 Rescue Dossier →